Changes to the Co-Primary Endpoint in the SENTRY Trial
Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a pharmaceutical company committed to advancing innovative cancer therapies, has made a crucial adjustment in their Phase 3 SENTRY trial focusing on myelofibrosis. Following valuable feedback from the U.S. Food and Drug Administration (FDA), the company is shifting the co-primary endpoint from Total Symptom Score Improvement of ? 50% (TSS50) to Absolute Total Symptom Score (Abs-TSS). This new endpoint will measure the average improvement in symptom scores over a 24-week period, allowing for a more accurate assessment of patient well-being.
Key Considerations Behind the Change
This decision is informed by data from a previous Phase 1 trial, which demonstrated significant enhancements in results when selinexor was administered alongside ruxolitinib. The trial indicated that approximately 80% of patients achieved a spleen volume response rate (SVR35), nearly doubling the results seen with traditional treatments alone. The average improvement in the Abs-TSS metric was noted at an impressive 18.5 points by the 24-week assessment. Such results affirm Karyopharm's belief that the SENTRY trial design will more effectively address the symptoms and treatment needs of patients suffering from myelofibrosis.
Expanding the Study Sample Size for Enhanced Results
To ensure adequate statistical power, Karyopharm is proactively increasing the sample size of the SENTRY trial to approximately 350 patients. This adjustment is anticipated to afford a more substantial validation of the outcomes observed, with top-line results still expected to be released in the latter half of 2025. The enthusiasm surrounding this trial is amplified by findings that confirm the urgent need for treatments that are more effective than current JAK inhibitor therapies.
Expert Opinions on the Trial’s Design
Dr. Raajit Rampal, a recognized authority in the field and Director of the Center for Hematologic Malignancies, expressed confidence in the trial's new direction. He emphasized the unmet need in treating myelofibrosis and the potential for significant enhancements in patient care through the adjusted study parameters. His viewpoint is shared by many leading figures in the medical community, highlighting the critical nature of adopting improved measures like Abs-TSS.
The Importance of Patient-Centric Outcomes
Adopting Abs-TSS as a co-primary endpoint aligns with ongoing conversations about the importance of patient-centric outcomes in clinical trials. It not only addresses a more holistic view of patient health but is also seen as a progressive step for similar studies in myelofibrosis. Key investigators and patient advocacy groups have generally supported the shift, which indicates a growing recognition of the complexity surrounding symptom management in serious illnesses.
Ongoing Engagement and Transparency
Karyopharm is committed to maintaining transparency with stakeholders and patients alike. They will be hosting a conference call to discuss the SENTRY trial updates in detail and to address any questions about the shift in endpoints, expected enrollments, and clinical outcomes. Engaging with the community allows Karyopharm to reinforce its objective of focusing on patient health through improved therapies and research.
The Significance of the SENTRY Trial
The SENTRY trial, designated as NCT04562389, compares the efficacy of a weekly dose of selinexor in conjunction with twice-daily ruxolitinib against a placebo arm. This design is poised to shed light on vital treatment parameters in JAKi naïve patients with myelofibrosis, who have traditionally had limited options. The two-to-one randomization toward the selinexor group aims to provide comprehensive insight into the treatment’s effectiveness.
Understanding XPOVIO in Cancer Therapy
Selinexor, marketed under the brand name XPOVIO, is an oral exportin 1 (XPO1) inhibitor that represents Karyopharm's pioneering efforts in targeted cancer therapies. Approved in multiple oncology indications, XPOVIO has shown promising results in treating conditions such as multiple myeloma and diffuse large B-cell lymphoma. As research expands, Karyopharm continues to uncover the therapeutic potential of selinexor, with investigations in various high-unmet-need cancers.
Frequently Asked Questions
What is the SENTRY trial and what is its focus?
The SENTRY trial is a pivotal Phase 3 clinical trial evaluating the efficacy of selinexor in combination with ruxolitinib in patients with myelofibrosis.
What change was made to the trial's endpoints?
The co-primary endpoint was changed from Total Symptom Score Improvement (TSS50) to Absolute Total Symptom Score (Abs-TSS) to better assess patient symptoms.
Why is the trial sample size increasing?
Karyopharm is increasing the sample size to approximately 350 patients to enhance the statistical power and validity of the study results.
What are the expectations for trial results?
Top-line results from the SENTRY trial are expected to be reported in the second half of 2025.
How does selinexor benefit patients?
Selinexor has shown significant improvements in symptom management and spleen volume response in patients with myelofibrosis in early trials.
